Business Standard

Granules India

Promoter of Granules India sells 3.09% stake for Rs 304 cr via open market

Krishna Prasad Chigurupati, one of the promoters of Granules India, on Wednesday pared a 3.09 per cent stake in the company for Rs 304 crore through an open market transaction. According to the block deal data available on the NSE, Krishna Prasad Chigurupati offloaded 75 lakh shares, amounting to a 3.09 per cent stake in Granules India. The shares were disposed of at an average price of Rs 405.08 apiece, taking the deal size to Rs 303.81 crore, as per the data on the National Stock Exchange (NSE). According to a regulatory filing on Wednesday, Granules India said the primary objectives of the deal was to clear personal debt, to release the existing pledge on his holding in the company, and creating a small personal liquidity. "Chigurupati further notified the company that he has no plans to sell his shareholding in Granules India Ltd in the foreseeable future. "Post this transaction, the total promoter & promoter group shareholding in the company has changed from 41.96 per cent to

Promoter of Granules India sells 3.09% stake for Rs 304 cr via open market
Updated On : 22 May 2024 | 10:00 PM IST

Granules India Q4 results: Revenue declines 1.6% on weak paracetamol sales

The company's consolidated revenue fell year-on-year to 1,176 crore rupees (nearly $141 million) for the three months to March 31

Granules India Q4 results: Revenue declines 1.6% on weak paracetamol sales
Updated On : 15 May 2024 | 2:19 PM IST

Aarti Drugs, Balrampur: 5 stocks that can surge up to 66% in Samvat 2080

Bayer Cropscience, Granules India and HLE Glasscoat are the other three stocks that can generate healthy returns till next Diwali, based on the existing chart patterns.

Aarti Drugs, Balrampur: 5 stocks that can surge up to 66% in Samvat 2080
Updated On : 10 Nov 2023 | 12:34 PM IST

Granules India's Q2 revenue rises 3.4% on higher sales in North America

Its shares gained 19.5% in the September-quarter, outperforming the Nifty pharma index, which climbed 12%

Granules India's Q2 revenue rises 3.4% on higher sales in North America
Updated On : 09 Nov 2023 | 5:02 PM IST

Paracetamol maker Granules India flags operations hit from cyber attack

Due to significant changes in its IT systems, the IT security incident caused a major disruption in its business operations, the Paracetamol maker said in an exchange filing

Paracetamol maker Granules India flags operations hit from cyber attack
Updated On : 29 Jun 2023 | 2:02 PM IST

Granules profit up 7.8% to Rs 120 crore boosted by drug ingredient business

Granules India reported a 7.8% rise in fourth-quarter profit, spurred by strong growth in its business of making active pharmaceutical ingredient (API) for drugs

Granules profit up 7.8% to Rs 120 crore boosted by drug ingredient business
Updated On : 16 May 2023 | 6:41 PM IST

Sensex sheds 413 pts as HDFC twins, RIL weigh; Nifty ends below 18,300

CLOSING BELL: The BSE Midcap, Smallcap indices, however, bucked the trend and ended with a gain of up to 0.2 per cent. Breadth too was marginally positive.

Sensex sheds 413 pts as HDFC twins, RIL weigh; Nifty ends below 18,300
Updated On : 16 May 2023 | 3:59 PM IST

Indian pharma firm Granules opens packaging facility in US' Virginia

Indian pharmaceutical company Granules has opened a packaging facility in the Virginia State of the US to expand the packaging capacity of essential drugs in the state, thus strengthening the biopharma supply chain. The facility was inaugurated by India's Ambassador to the US Taranjit Singh Sandhu. Granules, which was one of the first Indian pharmaceutical companies that received FDA authorization to export to the United States, has invested more than USD 100 million in the country, said Dr Krishna Prasad Chigurupati, the founder, chairman and managing director of the firm. "We have nearly 200 employees in Virginia with a large majority of them first-generation Indians," he said, adding the company also has a team of 30 scientists for research and development. Granules India Ltd produces some of the most widely used drugs, including Paracetamol, that have been very useful to billions across the world, Chigurupati said. "Happy to see Made in India' medicines value added in the US b

Indian pharma firm Granules opens packaging facility in US' Virginia
Updated On : 30 Mar 2023 | 8:47 AM IST

Granules gets USFDA nod to market generic medicine for high blood pressure

Drug firm Granules India on Monday said it has received approval from the US health regulator to market a generic product to treat high blood pressure. The company has received approval from the US Food & Drug Administration (USFDA) to market Losartan Potassium tablets in strengths of 25 mg, 50 mg, and 100 mg, Granules India said in a regulatory filing. The Hyderabad-based company's product is bioequivalent to the Organon LLC's Cozaar tablets. According to IQVIA/IMS Health, the current annual US market for Losartan potassium tablets is around USD 336 million. Shares of the company were trading 1.24 per cent down at Rs 281.75 apiece on the BSE.

Granules gets USFDA nod to market generic medicine for high blood pressure
Updated On : 27 Feb 2023 | 12:00 PM IST

Stocks to watch: SpiceJet, IOC, Granules India, Phoenix Mills, ABB India

Stocks to watch: From SpiceJet to Indian Oil Corporation, here are top stocks likely to be in action in Monday's trading session

Stocks to watch: SpiceJet, IOC, Granules India, Phoenix Mills, ABB India
Updated On : 27 Feb 2023 | 7:29 AM IST

Granules forges strategic partnership with Greenko ZeroC for Kakinada plant

Under the collaboration, Greenko ZeroC will be supplying carbon free energy and enable green hydrogen along with its various chemical derivatives

Granules forges strategic partnership with Greenko ZeroC for Kakinada plant
Updated On : 03 Jan 2023 | 3:24 PM IST

Paracetamol maker Granules India Q2 net profit jumps 80% to Rs 145 cr

Pharmaceutical company Granules India Ltd reported an 80% surge in quarterly profit on Thursday, boosted by higher sales of painkiller drug Paracetamol

Paracetamol maker Granules India Q2 net profit jumps 80% to Rs 145 cr
Updated On : 20 Oct 2022 | 3:51 PM IST

Nifty Pharma index surpasses 200-DMA; Cipla, Granules can soar up to 15%

The Pharma benchmark has outperformed the overall market in recent trading sessions; sustenance above 200-DMA is likely to trigger further gains for it

Nifty Pharma index surpasses 200-DMA; Cipla, Granules can soar up to 15%
Updated On : 04 Oct 2022 | 11:05 PM IST

Stocks to Watch: ACC, Ambuja, Adani Power, ONGC, Zomato, Hero MotoCorp

Stocks to Watch Today: In the F&O space, Indiabulls Housing Finance, India Cements, PVR and RBL Bank are in the ban period on Monday

Stocks to Watch: ACC, Ambuja, Adani Power, ONGC, Zomato, Hero MotoCorp
Updated On : 19 Sep 2022 | 8:47 AM IST

Derivatives analyst Nandish Shah recommends Bull Spread on Granules India

The analyst from HDFC Securities recommends buying Granules India 320 Call and simultaneously selling 340 Call of the September series.

Derivatives analyst Nandish Shah recommends Bull Spread on Granules India
Updated On : 16 Sep 2022 | 7:52 AM IST

Centrum Broking gives 'buy' call for Vijaya Diagnostic, Granules India

Brokerage house Centrum Broking has given a 'buy' call for Vijaya Diagnostic Centre and Granules India stocks

Centrum Broking gives 'buy' call for Vijaya Diagnostic, Granules India
Updated On : 09 Feb 2022 | 6:49 PM IST

Granules India, IOL Chemicals hit 52-week lows on weak Q2 results

IOL Chemicals slipped 10% to Rs 487, while Granules was down 8% to 285.80 on the BSE in intra-day trade

Granules India, IOL Chemicals hit 52-week lows on weak Q2 results
Updated On : 15 Nov 2021 | 2:32 PM IST

Drug firms Granules India, Jubilant Cadista recall products in US market

Jubilant Cadista is a fully-owned subsidiary of Cadista Holdings Inc, which is a part of the Noida-based Jubilant Life Sciences Company.

Drug firms Granules India, Jubilant Cadista recall products in US market
Updated On : 12 Sep 2021 | 1:25 PM IST

Drug firm Granules India Q1 consolidated net profit up 8% to Rs 120 cr

Drug firm Granules India on Tuesday reported an 8 per cent rise in its consolidated net profit to Rs 120 crore for the quarter ended June 30, 2021.

Drug firm Granules India Q1 consolidated net profit up 8% to Rs 120 cr
Updated On : 27 Jul 2021 | 11:08 PM IST

Two stocks that Vaishali Parekh of Prabhudas Lilladher is bullish on

The stock of Tata Chemicals has maintained a good support base near Rs 690 levels and picked up momentum currently

Two stocks that Vaishali Parekh of Prabhudas Lilladher is bullish on
Updated On : 07 Jun 2021 | 8:35 AM IST